Description

Haemonetics Corporation: Diversification Into High-Margin Med-Surg Offerings As A Critical Growth Lever!

Haemonetics Corporation reported its third-quarter fiscal 2025 financial results, indicating both strengths and challenges within its various business segments. The company achieved a revenue of $349 million, reflecting a 4% increase on a reported basis but remaining flat organically. Adjusted earnings per share improved by 14% to $1.19. Despite facing external challenges, Haemonetics has managed to maintain margin expansion and earnings growth.

Our Report Structure:

⦁ Company Overview
⦁ Investment Thesis
⦁ Key Drivers
⦁ Historical Quarterly Statement Analysis – Income Statement & Cash Flows
⦁ Historical Quarterly Balance Sheet Analysis
⦁ Historical Annual Financial Statement Analysis
⦁ Analysis Of Key Financial Ratios
⦁ Financial Forecasts For 3 Years
⦁ Forecasting The Capital Structure & Net Debt
⦁ Discounted Cash Flow Valuation
⦁ Trading Multiples
⦁ Key Risks
⦁ Disclosures

Want unlimited access to our reports? Purchase our $99 annual subscription!